<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="case-report" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Mol Cytogenet</journal-id>
<journal-id journal-id-type="iso-abbrev">Mol Cytogenet</journal-id>
<journal-title-group>
<journal-title>Molecular Cytogenetics</journal-title>
</journal-title-group>
<issn pub-type="epub">1755-8166</issn>
<publisher>
<publisher-name>BioMed Central</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27486480</article-id>
<article-id pub-id-type="pmc">4970234</article-id>
<article-id pub-id-type="publisher-id">269</article-id>
<article-id pub-id-type="doi">10.1186/s13039-016-0269-1</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Case Report</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Partial monosomy14q involving <italic>FOXG1</italic> and <italic>NOVA1</italic> in an infant with microcephaly, seizures and severe developmental delay</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Fryssira</surname>
<given-names>H.</given-names>
</name>
<address>
<email>efrysira@med.uoa.gr</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tsoutsou</surname>
<given-names>E.</given-names>
</name>
<address>
<email>irenets78@hotmail.com</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Psoni</surname>
<given-names>S.</given-names>
</name>
<address>
<email>psonistavroula@gmail.com</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Amenta</surname>
<given-names>S.</given-names>
</name>
<address>
<email>amenta@hol.gr</email>
</address>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liehr</surname>
<given-names>T.</given-names>
</name>
<address>
<email>Thomas.Liehr@med.uni-jena.de</email>
</address>
<xref ref-type="aff" rid="Aff6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Anastasakis</surname>
<given-names>E.</given-names>
</name>
<address>
<email>loufty28@yahoo.gr</email>
</address>
<xref ref-type="aff" rid="Aff7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Skentou</surname>
<given-names>Ch</given-names>
</name>
<address>
<email>haraskent@yahoo.gr</email>
</address>
<xref ref-type="aff" rid="Aff5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ntouflia</surname>
<given-names>A.</given-names>
</name>
<address>
<email>ntouflia@gmail.com</email>
</address>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Papoulidis</surname>
<given-names>I.</given-names>
</name>
<address>
<email>papoulidis@atg-labs.gr</email>
</address>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Manolakos</surname>
<given-names>E.</given-names>
</name>
<address>
<email>manolakos@atg-labs.gr</email>
</address>
<xref ref-type="aff" rid="Aff3">3</xref>
<xref ref-type="aff" rid="Aff8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chaliasos</surname>
<given-names>N.</given-names>
</name>
<address>
<email>nchalias@cc.uoi.gr</email>
</address>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<aff id="Aff1"><label>1</label>Medical genetics, School of Medicine, National and Kapodistrian University of Athens, “Aghia Sophia” Children’s Hospital, Athens, Greece </aff>
<aff id="Aff2"><label>2</label>“Mitera” Maternity Hospital, Athens, Greece </aff>
<aff id="Aff3"><label>3</label>“Access to Genome” Clinical Laboratory Genetics, Athens Thessaloniki, Greece </aff>
<aff id="Aff4"><label>4</label>Child Health Department, University Hospital of Ioannina (UHI), Ioannina, Greece </aff>
<aff id="Aff5"><label>5</label>“Mitera kai emvrio” Medical centre, Larisa, Greece </aff>
<aff id="Aff6"><label>6</label>Institute of Human Genetics, Jena University Hospital, Friedrich Schiller University, Jena, Germany </aff>
<aff id="Aff7"><label>7</label>Hellenic Navy Hospital, Deinokratous 70, Athens, 11521 Greece </aff>
<aff id="Aff8"><label>8</label>Department of Medical Genetics, Binaghi Hospital, University of Cagliari, Cagliari, Italy </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>2</day>
<month>8</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>2</day>
<month>8</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="collection">
<year>2016</year>
</pub-date>
<volume>9</volume>
<elocation-id>55</elocation-id>
<history>
<date date-type="received">
<day>28</day>
<month>4</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>25</day>
<month>7</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s). 2016</copyright-statement>
<license license-type="OpenAccess">
<license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<sec>
<title>Background</title>
<p><italic>FOXG1</italic> gene mutations have been associated with the congenital variant of Rett syndrome (RTT) since the initial description of two patients in 2008. The on-going accumulation of clinical data suggests that the FOXG1-variant of RTT forms a distinguishable phenotype, consisting mainly of postnatal microcephaly, seizures, hypotonia, developmental delay and corpus callosum agenesis.</p>
</sec>
<sec>
<title>Case presentation</title>
<p>We report a 6-month-old female infant, born at 38 weeks of gestation after in vitro fertilization, who presented with feeding difficulties, irritability and developmental delay from the first months of life. Microcephaly with bitemporal narrowing, dyspraxia, poor eye contact and strabismus were also noted. At 10 months, the proband exhibited focal seizures and required valproic acid treatment. Array-Comparative Genomic Hybridization revealed a 4.09 Mb deletion in 14q12 region, encompassing the <italic>FOXG1</italic> and <italic>NOVA1</italic> genes. The proband presented similar feature with patients with 14q12 deletions except for dysgenesis of corpus callosum. Disruption of the <italic>NOVA1</italic> gene which promotes the motor neurons apoptosis has not yet been linked to any human phenotypes and it is uncertain if it affects our patient’s phenotype.</p>
</sec>
<sec>
<title>Conclusions</title>
<p>Since our patient is the first reported case with deletion of both genes (<italic>FOXG1-NOVA1</italic>), thorough clinical follow up would further delineate the Congenital Rett-Variant phenotypes.</p>
</sec>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>FOXG1 syndrome</kwd>
<kwd>Rett syndrome</kwd>
<kwd>
<italic>NOVA1</italic>
</kwd>
<kwd>Array-CGH</kwd>
<kwd>Postnatal microcephaly</kwd>
<kwd>Seizures</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution>Access to genome P.C., Clinical Laboratory Genetics, 33A Ethn. Antistaseos str, 55134 Thessaloniki, Greece</institution>
</funding-source>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2016</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Background</title>
<p>Since 2008, when mutations in the <italic>FOXG1</italic> gene were initially described in two patients with Rett-like symptoms, more than 90 patients have been reported to have mutations involving the <italic>FOXG1</italic> gene [<xref ref-type="bibr" rid="CR1">1</xref>–<xref ref-type="bibr" rid="CR6">6</xref>]. Rett syndrome is typically an X-linked neurodegenerative condition [<xref ref-type="bibr" rid="CR6">6</xref>] that was initially described by Andreas Rett in 1966. Common clinical features of Rett syndrome include postnatal microcephaly, autism, seizures, breathing abnormalities, growth retardation and gait apraxia [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. The majority of patients with typical Rett syndrome carry mutations in the gene encoding Methyl-CpG-binding protein 2 (<italic>MECP2</italic>) located at Xq28. Variant forms of Rett syndrome have been revised in 2010 by Neul et al [<xref ref-type="bibr" rid="CR7">7</xref>]. He classified them in to three main variant categories: 1. Preserved speech, 2. early seizures and, 3. the congenital variant. Mutations in the cyclin-dependent kinase-like 5 (<italic>CDKL5)</italic> gene located in Xp22 are found in most cases of early-onset seizure variants, while the congenital variant of the syndrome has recently been found to be associated with heterozygous mutations or deletions in the forkhead box protein G1 (<italic>FOXG1</italic>) gene, located in the 14q12 chromosomal region [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR9">9</xref>–<xref ref-type="bibr" rid="CR11">11</xref>]. In this study, we report a new case of atypical Rett Syndrome with a 14q12 deletion, 4.09 Mb in size, encompassing only two genes, the <italic>FOXG1</italic> and the <italic>NOVA1</italic> and we discuss the role of the <italic>NOVA1</italic> haploinsufficiency.</p>
</sec>
<sec id="Sec2">
<title>Case presentation</title>
<p>Our patient was a 6-month- old female infant and the only child of non-consanguineous parents. She was born by caesarean section at 38 weeks of gestation. Her birth weight was 2.990 gr (25<sup>th</sup> -50<sup>th</sup> centile), her length was 49 cm (25<sup>th</sup> -50<sup>th</sup> centile) and her head circumference was 33 cm (10–25th centile).</p>
<p>It should be noted that the embryo was the product of in vitro fertilization (IVF) by intracytoplasmic sperm injection (ICSI) due to the husband’s low sperm count. The mother underwent treatment with Follitropin Beta (Puregon), human Chorionic Gonadotropin, hCG (Pregnyl), and Cetrorelix Acetate (Cetrotide).</p>
<p>The patient as a neonate was hypotonic. She was referred for clinical evaluation at the age of 6 months due to irritability and feeding difficulties. The examinations revealed peripheral hypertonia, psychomotor retardation (limited facial expression—no smile, poor eye contact), borderline microcephaly (head circumference of 39 cm, at 3<sup>rd</sup> centile) (Fig. <xref ref-type="fig" rid="Fig1">1a</xref>), periodical stereotypic movements and minor dysmorphic features such as a small forehead with bitemporal narrowing, strabismus, broad base to nose and long philtrum. Her weight was 6.18 kg (25th centile) and her height was 62 cm (25th centile).<fig id="Fig1"><label>Fig. 1</label><caption><p>Growth curve ¨Head circumference—for—age GIRLS. First Paediatric department, National and Kapodistrian University of Athens. Professor G.Chroussos. The standard curves are used by the Greek National Health System</p></caption><graphic id="MO1" xlink:href="13039_2016_269_Fig1_HTML"></graphic></fig></p>
<p>Due to gastroesophageal reflux she was treated with ranitidine.</p>
<p>Haematological, biochemical, metabolic, thyroid, ammonia and blood gasses were all normal. The ultrasounds of the heart and abdomen were also normal.</p>
<p>At 10 months the proband exhibited focal seizures and required valproic acid treatment. Sleep deprived EEG examination revealed slower focal activity for her age and sleep spindles which are indicative signs of focal cerebral dysfunction. Brain magnetic resonance imaging (MRI) showed no serious findings except for a septum pellucidum cyst and brain asymmetry—the left hemisphere was larger than the right one.</p>
<p>At the age of 12 months, the head circumference was 40.7 cm (&lt;&lt; 3<sup>rd</sup> centile) (Fig. <xref ref-type="fig" rid="Fig1">1a</xref>) while the height and weight remained between 10<sup>th</sup> and 25<sup>th</sup> centile. Severe neurodevelopmental delay was obvious.</p>
<p>Re-examination at the age of 19- months and 2-years, revealed head circumference of 42 cm (&lt;&lt; 3<sup>rd</sup> centile) (Fig. <xref ref-type="fig" rid="Fig1">1a</xref>), height of 75.5 cm (slightly below the 3<sup>rd</sup> centile) and weight of 9 Kg (slightly below the 3<sup>rd</sup> centile). The proband exhibited severe psychomotor retardation as she could neither sit independently nor speak at all.</p>
<sec id="Sec3">
<title>Chromosome and array-based analysis</title>
<p>Metaphase chromosomes were obtained from phytohemagglutinin (PHA)-stimulated peripheral blood lymphocytes and high resolution (550–650 bands) thymidine treatment G-banding karyotype analysis was performed, using standard procedures. Twenty metaphase spreads were analysed, and the result was a normal female karyotype (46, XX). The molecular analysis of the <italic>MECP2</italic> gene was normal also.</p>
<p>Further investigation with array-Comparative Genomic Hybridization was performed by hybridizing the sample against a male human reference commercial DNA sample (Promega biotech) using an array-CGH platform that includes 60,000 oligonucleotides distributed across the entire genome (Agilent Technologies). The statistical test used as parameter to estimate the number of copies was ADAM-2 (provided by the DNA analytics software, Agilent Techn.) with a window of 0.5 Mb, A = 6. Only those copy number changes that affect at least 5 consecutive probes with identically oriented change were considered as Copy Number Variations (CNV). For the majority of the genome, the average genomic power of resolution of this analysis was 200 kilobases. Array-CGH analysis detected a 4.09 Mb loss in the 14q12 region (Fig. <xref ref-type="fig" rid="Fig2">2a</xref>). The deleted segment was mapped at chr14:25,843,560-29,938,629 region. The genomic coordinates are listed according to genomic build GRCh37/hg19, and includes <italic>FOXG1</italic> and <italic>NOVA1</italic> genes (Fig. <xref ref-type="fig" rid="Fig2">2b</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Array-CGH analysis detected a 4.09 Mb loss of the copy numbers in the spanning region 14q12. <bold>b</bold> Chromosome 14, region 25,843,560-29,938,629. Represents the 4,095,070 bp deletion described in our case report. The region includes both <italic>FOXG1</italic> and <italic>NOVA1</italic> genes. Figure adapted from <ext-link ext-link-type="uri" xlink:href="http://genome.ucsc.edu/">http://genome.ucsc.edu/</ext-link> Accessed at 18/10/2015</p></caption><graphic id="MO2" xlink:href="13039_2016_269_Fig2_HTML"></graphic></fig><fig id="Fig3"><label>Fig. 3</label><caption><p>Ideogram of the deletions described in Table <xref ref-type="table" rid="Tab1">1</xref>. The upper thin line indicates the 14q12 region (hg38), and the bold lines indicate the region which is deleted in each case. Cellini et al. 2015 case 3 has a deletion beyond 14q12 and is drawn with a discontinued line</p></caption><graphic id="MO3" xlink:href="13039_2016_269_Fig3_HTML"></graphic></fig></p>
<p>The result of array-CGH was confirmed with FISH. Ten metaphases were analysed from phytohemagglutinin (PHA)-stimulated peripheral blood lymphocytes of the patient with RP11-120I18 in 14q12 and wcp 14 probes. The rearrangement was molecular cytogenetically unbalanced (data not shown), therefore the karyotype is: 46,XX, del[<xref ref-type="bibr" rid="CR12">12</xref>](q12q12).ish14q12(RP11-120I18-). arr[hg19]14q12(25,843,560-29,938,629)x1. Blood samples from both parents were examined with FISH in order to exclude any chromosome rearrangement like inversion. Ten metaphases were analysed from each subject with RP11-332 N6 in 14q11.2, RP11-120I18 in 14q12 and wcp 14 probes, and no rearrangement was detected (data not shown).</p>
</sec>
</sec>
<sec id="Sec4">
<title>Discussion</title>
<p>Recently, the <italic>FOXG1</italic> congenital variant of Rett syndrome has been described as a clinically identifiable phenotype, called the “<italic>FOXG1</italic> syndrome” [<xref ref-type="bibr" rid="CR13">13</xref>]. This is an epileptic-dyskinetic developmental encephalopathy with features of classic Rett syndrome, but earlier onset from the first months of life. The main phenotype comprises postnatal microcephaly, severe developmental delay and lack of speech, hypotonia, dyskinesia and corpus callosum hypoplasia. Other symptoms include strabismus, feeding difficulties, bruxism and seizures [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR12">12</xref>–<xref ref-type="bibr" rid="CR16">16</xref>].</p>
<p>In the present study, a novel <italic>FOXG1</italic> and a <italic>NOVA1</italic> deletion is described. According to the diagnostic criteria for typical and atypical Rett syndrome [<xref ref-type="bibr" rid="CR7">7</xref>], our patient possesses only some of the diagnostic criteria for the atypical Rett syndrome. She has slight facial dysmorphism, feeding difficulties, severe psychomotor retardation, postnatal microcephaly, seizures and focal cerebral dysfunction, strabismus and hypertonia. A deletion of 4.09 Mb on chromosome 14q12 including the <italic>FOXG1</italic> and <italic>NOVA1</italic> genes was identified by array-CGH technique<italic>.</italic> The clinical phenotypes vary between the reported cases that have mutations or deletions involving the <italic>FOXG1</italic> gene and other genes (Table <xref ref-type="table" rid="Tab1">1</xref>, Fig. <xref ref-type="fig" rid="Fig3">3</xref>). Our case differs as only two genes, <italic>FOXG1</italic> and <italic>NOVA1</italic>, are involved. These genes were found to be highly expressed in the human brain throughout ontogeny, and double strand breaks in 14q12 region are implicated in the neurodegenerative disease: ataxia telangiectasia [<xref ref-type="bibr" rid="CR17">17</xref>].<table-wrap id="Tab1"><label>Table 1</label><caption><p>Clinical presentation of patients with FOXG1 mutations and 14q12 deletions</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"></th><th rowspan="2">
<italic>Kumakura</italic> et al<italic>. 2014</italic>
</th><th rowspan="2">
<italic>Byun</italic> et al<italic>. 2015</italic>
</th><th colspan="5">
<italic>Patients (n = 8) Cellini</italic> et al<italic>. 2015</italic>
</th><th rowspan="2">
<italic>Patients (n = 7) Allou</italic> et al<italic>. 2012</italic>
</th><th rowspan="2">
<italic>Patients (n = 2) Philippe</italic> et al<italic>. 2011</italic>
</th><th rowspan="2">
<italic>Jacob</italic> et al<italic>. 2009</italic>
</th><th rowspan="2">
<italic>Yeung</italic> et al<italic>. 2009</italic>
</th><th rowspan="2">
<italic>Patients (n = 2) Ariani</italic> et al<italic>. 2008</italic>
</th><th rowspan="2">
<italic>Papa</italic> et al<italic>. 2008</italic>
</th><th rowspan="2">
<italic>Present case</italic>
</th></tr><tr><th>
<italic>1</italic>
</th><th>
<italic>2</italic>
</th><th>
<italic>3</italic>
</th><th>
<italic>4</italic>
</th><th>
<italic>4 cases with point mutations in FOXG1</italic>
</th></tr></thead><tbody><tr><td>Age (Y,M)</td><td>8.0</td><td>8.0</td><td>9.0</td><td>3.6</td><td>2.0</td><td>10.0</td><td>2.6–17.0</td><td>N/A</td><td>22.0 and 10.0</td><td>3.0</td><td>9.0</td><td>22.0 and 7.0</td><td>7.0</td><td>0.6</td></tr><tr><td>Sex</td><td>M</td><td>F</td><td>F</td><td>M</td><td>F</td><td>F</td><td>3 F, 1 M</td><td>4 F, 3 M</td><td>F</td><td>F</td><td>F</td><td>F</td><td>F</td><td>F</td></tr><tr><td>FOXG1 mutation on 14q12 CNV (Mb)</td><td>0.54 Mb Del</td><td>2.5 Mb Del</td><td>2.5 Mb Del</td><td>2.8 Mb Del</td><td>9.1 Mb Del</td><td>7.3 Mb Dup (de novo)</td><td>p.Gln100Serfs*92, p.Q46X, p.Glu154Glyfs*301, p.Gln86Argfs*106 (de novo)</td><td>0.4–4.1 Mb</td><td>p.Trp308X and p.Tyr400X</td><td>2.594 Mb Del</td><td>4.45 Mb Dup</td><td>p.W255X and p.S323fsX325</td><td>3 Mb Del</td><td>4,09 Del</td></tr><tr><td>Genes involved in mutation or point mutations</td><td>
<italic>FOXG1, C14orf23 (de novo)</italic>
</td><td>
<italic>FOXG1, C14orf23, PRKD1</italic> (de novo)</td><td>
<italic>FOXG1, C14orf23, PRKD1</italic>
</td><td>
<italic>FOXG1, C14orf23, PRKD1, SCFD1, G2E3, COCH, STRN3</italic> (de novo)</td><td>
<italic>STXBP6, NOVA1, FOXG1, C14orf23, PRKD1, SCFD1, G2E3, COCH, STRN3, AP4S1, HECTD1, DTD2, NUBPL, ARHGAP5, AKAP, NPAS3</italic> (de novo)</td><td>
<italic>FOXG1 and 50 additional genes (de novo)</italic>
</td><td>
<italic>FOXG1</italic>
</td><td>
<italic>Deletions in 5 cases, 3 of them distal to FOXG1 and 2 cases of point mutations involving FOXG1</italic>
</td><td>
<italic>FOXG1</italic>
</td><td>
<italic>FOXG1</italic>, <italic>C14orf23</italic>
</td><td>
<italic>FOXG1, NOVA1, c14orf23, PRKD1, G2E3, SDFD, COCH</italic>
</td><td>
<italic>FOXG1</italic>
</td><td>
<italic>FOXG1, PRKD1, SCFD1, G2E3, COCH, STRN3</italic>
</td><td>
<italic>FOXG1, NOVA1</italic>
</td></tr><tr><td>Postnatal microcephaly</td><td>yes</td><td>yes</td><td>yes</td><td>yes</td><td>yes</td><td>no</td><td>yes</td><td>yes</td><td>yes</td><td>yes</td><td>no</td><td>yes</td><td>yes</td><td>yes</td></tr><tr><td>Psychomotor retardation</td><td>yes</td><td>yes</td><td>yes</td><td>yes</td><td>yes</td><td>yes</td><td>yes</td><td>yes</td><td>yes</td><td>yes</td><td>yes</td><td>yes</td><td>yes</td><td>yes</td></tr><tr><td>Hypotonia</td><td>yes</td><td>no</td><td>yes</td><td>yes</td><td>yes</td><td>yes</td><td>2/4 cases hypotonic</td><td>All except 1 case</td><td>1/2 cases</td><td>yes</td><td>yes</td><td>yes</td><td>yes</td><td>Hypertonia</td></tr><tr><td>Diskinesia</td><td>yes</td><td>yes</td><td>yes</td><td>yes</td><td>yes</td><td>yes</td><td>3/4 cases diskinetic</td><td>3/7 cases</td><td>yes</td><td>yes</td><td>yes</td><td>yes</td><td>yes</td><td>yes</td></tr><tr><td>Speech</td><td>no</td><td>no</td><td>no</td><td>no</td><td>no</td><td>no</td><td>no</td><td>no</td><td>no</td><td>no</td><td>no</td><td>no</td><td>no</td><td>no</td></tr><tr><td>Hand stereotypies</td><td>no</td><td>other sterotypies</td><td>yes</td><td>no</td><td>yes</td><td>yes</td><td>yes</td><td>4/7 cases</td><td>yes</td><td>yes</td><td>hand flapping only</td><td>yes</td><td>yes</td><td>yes</td></tr><tr><td>Corpus callosum hypogenesis</td><td>yes</td><td>no</td><td>yes</td><td>yes</td><td>yes</td><td>no</td><td>3/4 cases with hypoplasia</td><td>brain abnormalities in all cases</td><td>1/2 cases</td><td>no, brachycephaly observed</td><td>no</td><td>yes</td><td>no</td><td>no</td></tr><tr><td>Seizures</td><td>yes</td><td>yes</td><td>yes</td><td>yes</td><td>yes</td><td>yes</td><td>yes</td><td>5/7 cases</td><td>1/2 cases</td><td>yes</td><td>yes</td><td>yes</td><td>yes</td><td>yes</td></tr><tr><td>Developmental delay</td><td>yes</td><td>yes</td><td>yes</td><td>yes</td><td>yes</td><td>yes</td><td>yes</td><td>5/7 cases</td><td>1/2 cases</td><td>yes</td><td>yes</td><td>yes</td><td>yes</td><td>yes</td></tr></tbody></table><table-wrap-foot><p>
<italic>F</italic> female, <italic>M</italic> male, <italic>Y</italic> years, <italic>M</italic> months, <italic>Del</italic> deletion, <italic>Dup</italic> duplication</p></table-wrap-foot></table-wrap></p>
<p>Different clinical features have also been described in patients with <italic>FOXG1</italic> point mutations. The severity or lack of the symptoms among cases could depend additionally on genetic and/or environmental factors [<xref ref-type="bibr" rid="CR13">13</xref>]. Jacob F. et al. in 2009 [<xref ref-type="bibr" rid="CR9">9</xref>] reported a case of a 2.594 Mb deletion involving the <italic>FOXG1</italic> and <italic>C23orf14</italic> (Table <xref ref-type="table" rid="Tab1">1</xref>). As in our case, patient had a normal corpus callosum but showed all the typical characteristics found in patients with <italic>FOXG1</italic> alterations. Table <xref ref-type="table" rid="Tab1">1</xref> indicates that almost all cases suffer from microcephaly, dyskinesia, lack of speech, seizures and developmental delay. On the other hand, hypotonia and corpus callosum hypoplasia are not apparent in every case. Progressive hypertonia was obvious in our patient and in at least 10 other reported cases with <italic>FOXG1</italic> point mutations [<xref ref-type="bibr" rid="CR8">8</xref>].</p>
<p>Forkhead BOX G1 <italic>(FOXG1)</italic> gene (OMIM<italic>*</italic>164874) encodes a developmental transcription factor with repressor activity, important for the development of the ventral telencephalon in the embryonic forebrain and crucial for the regulation of neurogenesis and neurite outgrowth. It is also expressed in neurogenetic regions of the postnatal brain [<xref ref-type="bibr" rid="CR15">15</xref>]. Postnatal microcephaly is another common feature of FOXG1 syndrome. In cases with a duplication of the <italic>FOXG1</italic> gene, microcephaly is not found (Table <xref ref-type="table" rid="Tab1">1</xref>), indicating that the phenotype is dependent on <italic>FOXG1</italic> dosage. Furthermore, other reported cases with deletions close but not disturbing the <italic>FOXG1</italic> gene have a similar phenotype as patients with ¨FOXG1 syndrome¨, suggesting that a position effect causing altered expression of <italic>FOXG1</italic> gene may be the cause. The protein Kinase D1 (<italic>PRKD1)</italic> gene (OMIM*605435), located close to <italic>FOXG1</italic> gene has been reported to be implicated in transcription and expression of <italic>FOXG1</italic> gene [<xref ref-type="bibr" rid="CR14">14</xref>].</p>
<p>Neuro-Oncological Ventral Antigen 1 (<italic>NOVA1)</italic> gene (OMIM*602157) encodes a neuron-specific RNA-binding protein that is inhibited by paraneoplastic antibodies [<xref ref-type="bibr" rid="CR18">18</xref>]. Recently, Storchel H et al., 2015 [<xref ref-type="bibr" rid="CR19">19</xref>] found that NOVA1 protein converges on Ago proteins and controls miRNA-induced silencing complex (miRISC), possibly resulting on the regulation of neuronal development and synaptic plasticity. Despite the significant role of the <italic>NOVA1</italic> gene, it has not been linked to any human phenotype yet. In the case of our patient with FOXG1 syndrome, we are unable to estimate the impact of the <italic>NOVA1</italic> haploinsufficiency. <italic>NOVA1</italic> haploinsufficiency may act synergistically with the <italic>FOXG1</italic> gene or it may cause no difference in the final clinical outcome. Also, we cannot define whether the IVF by ICSI plays a role in the microdeletion of chromosome 14q12 region. Further research should investigate if ICSI could be associated with haploinsufficiency as was the case in our patient.</p>
<p>In conclusion, we present a female patient with clinical features compatible with the congenital variant of Rett syndrome.</p>
</sec>
<sec id="Sec5">
<title>Conclusion</title>
<p>Since our patient is the only one with a deletion encompassing only <italic>FOXG1</italic> and <italic>NOVA1</italic> genes, in the future the thorough clinical follow-up of her neurological status will help for further delineation of the role of these genes.</p>
</sec>
<sec id="Sec6">
<title>Abbreviations</title>
<p>CGH, comparative genomic hybridization; EEG, electroencephalogram; ICSI, intracytoplasmic sperm injection; IVF, in vitro fertilization; MRI, magnetic resonance imaging; PHA, phytohemagglutinin; RTT, Rett syndrome</p>
</sec>
</body>
<back>
<ack>
<p>The authors would like to thank the members of the family of the patient for their collaboration.</p>
<sec id="FPar1">
<title>Funding</title>
<p>The whole study was funded by the private company Access to Genome, Clinical Laboratory Genetics, 33A Ethn. Antistaseos str, 55134 Thessaloniki, Greece.</p>
</sec>
<sec id="FPar2">
<title>Availability of data and materials</title>
<p>The datasets during and/or analysed during the current study are available from the corresponding author on reasonable request.</p>
</sec>
<sec id="FPar3">
<title>Authors’ contributions</title>
<p>AN and CS wrote the manuscript; HF, ET, SP and SA coordinated the clinical analysis of the patient; EM performed the cytogenetic analysis; IP signed out the molecular cytogenetic results; EM, IP and NC coordinated the study; All authors have read and approved the manuscript.</p>
</sec>
<sec id="FPar4">
<title>Competing interests</title>
<p>The authors declare that they have no competing interests.</p>
</sec>
<sec id="FPar5">
<title>Consent for publication</title>
<p>Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.</p>
</sec>
</ack>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ariani</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Hayek</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Rondinella</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>FOXG1 is responsible for the congenital variant of Rett syndrome</article-title>
<source/>Am J Hum Genet
          <year>2008</year>
<volume>83</volume>
<fpage>89</fpage>
<lpage>93</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2008.05.015</pub-id>
<pub-id pub-id-type="pmid">18571142</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takagi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sasaki</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Mitsui</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Honda</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hasegawa</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>A 2.0 Mb microdeletion in proximal chromosome 14q12, involving regulatory elements of FOXG1, with the coding region of FOXG1 being unaffected, results in severe developmental delay, microcephaly, and hypoplasia of the corpus callosum</article-title>
<source/>Eur J Med Genet
          <year>2013</year>
<volume>56</volume>
<issue>9</issue>
<fpage>526</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejmg.2013.05.012</pub-id>
<pub-id pub-id-type="pmid">23895774</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perche</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Haddad</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Menuet</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Callier</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Marcos</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Briault</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Laudier</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Dysregulation of FOXG1 pathway in a 14q12 microdeletion case</article-title>
<source/>Am J Med Genet
          <year>2013</year>
<volume>161A</volume>
<issue>12</issue>
<fpage>3072</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.36170</pub-id>
<pub-id pub-id-type="pmid">23956198</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ellaway</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Bettella</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Knapman</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Collins</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Hackett</surname>
<given-names>A</given-names>
</name>
<name>
<surname>McKenzie</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Darmanian</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>GB</given-names>
</name>
<name>
<surname>Fagan</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Christodoulou</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>14q12 microdeletions excluding FOXG1 give rise to a congenital variant Rett syndrome-like phenotype</article-title>
<source/>Eur J Hum Genet
          <year>2013</year>
<volume>21</volume>
<issue>5</issue>
<fpage>522</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1038/ejhg.2012.208</pub-id>
<pub-id pub-id-type="pmid">22968132</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stenson</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Mort</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ball</surname>
<given-names>EV</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>DN</given-names>
</name>
</person-group>
<article-title>The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnositic testing and personalized genomic medicine</article-title>
<source/>Hum Genet
          <year>2014</year>
<volume>133</volume>
<fpage>1</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1007/s00439-013-1358-4</pub-id>
<pub-id pub-id-type="pmid">24077912</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumakura</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Okajima</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hata</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>A haploinsufficiency of <italic>FOXG1</italic> identified in a boy with congenital variant of Rett syndrome</article-title>
<source/>Brain Dev
          <year>2014</year>
<volume>36</volume>
<issue>8</issue>
<fpage>725</fpage>
<lpage>729</lpage>
<pub-id pub-id-type="doi">10.1016/j.braindev.2013.09.006</pub-id>
<pub-id pub-id-type="pmid">24139857</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neul</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Kaufmann</surname>
<given-names>WE</given-names>
</name>
<name>
<surname>Glaze</surname>
<given-names>DG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Rett Syndrome: revised diagnostic criteria and nomenclature</article-title>
<source/>Ann Neurol
          <year>2010</year>
<volume>68</volume>
<fpage>944</fpage>
<lpage>50</lpage>
<pub-id pub-id-type="doi">10.1002/ana.22124</pub-id>
<pub-id pub-id-type="pmid">21154482</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<mixed-citation publication-type="other">Byun CK, Lee JS, Lim BC, Kim KJ, Hwang YS and Chae J. FOXG1 Mutation is a Low-Incidence Genetic Cause in Atypical Rett Syndrome. Child Neurology Open. 2015;8:1-5</mixed-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jacob</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Ramaswamy</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Andersen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bolduc</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Atypical Rett syndrome with selective FOXG1 deletion detected by comparative genomic hybridization: case report and review of literature</article-title>
<source/>Eur J Hum Genet
          <year>2009</year>
<volume>17</volume>
<fpage>1577</fpage>
<lpage>1581</lpage>
<pub-id pub-id-type="doi">10.1038/ejhg.2009.95</pub-id>
<pub-id pub-id-type="pmid">19623215</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papa</surname>
<given-names>FT</given-names>
</name>
<name>
<surname>Mencarelli</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Caselli</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A 3 Mb Deletion in 14q12 Causes Severe Mental Retardation, Mild Facial Dysmorphisms and Rett-like Features</article-title>
<source/>Am J Med Genet
          <year>2008</year>
<volume>146</volume>
<fpage>1994</fpage>
<lpage>1998</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.32413</pub-id>
<pub-id pub-id-type="pmid">18627055</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pantaleón</surname>
<given-names>FG</given-names>
</name>
<name>
<surname>Juvier</surname>
<given-names>RT</given-names>
</name>
</person-group>
<article-title>Molecular basis of Rett syndrome: A current look</article-title>
<source/>Rev Chil Pediatr
          <year>2015</year>
<volume>86</volume>
<fpage>142</fpage>
<lpage>51</lpage>
<pub-id pub-id-type="doi">10.1016/j.rchipe.2015.07.001</pub-id>
<pub-id pub-id-type="pmid">26239053</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Allou</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lambert</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Amsallem</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bieth</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Edery</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Destree</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>14q12 and severe Rett-like phenotypes: new clinical insights and physical mapping of FOXG1-regulatory elements</article-title>
<source/>Eur J Hum Genet
          <year>2012</year>
<volume>20</volume>
<fpage>1216</fpage>
<lpage>1223</lpage>
<pub-id pub-id-type="doi">10.1038/ejhg.2012.127</pub-id>
<pub-id pub-id-type="pmid">22739344</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kortüm</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Flindt</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Morris-Rosendahl</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Stefanova</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Goldstein</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The core FOXG1 syndrome phenotype consists of postnatal microcephaly, severe mental retardation, absent language, dyskinesia, and corpus callosum hypogenesis</article-title>
<source/>J Med Genet
          <year>2011</year>
<volume>48</volume>
<fpage>396</fpage>
<lpage>406</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.2010.087528</pub-id>
<pub-id pub-id-type="pmid">21441262</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pratt</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Warner</surname>
<given-names>JV</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>MG</given-names>
</name>
</person-group>
<article-title>Genotyping FOXG1 mutations in patients with clinical evidence of the FOXG1 syndrome</article-title>
<source/>Mol Syndromol
          <year>2013</year>
<volume>3</volume>
<issue>6</issue>
<fpage>284</fpage>
<lpage>287</lpage>
<pub-id pub-id-type="pmid">23599699</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Florian</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bahi-Buisson</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Bienvenu</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>FOXG1-related disorders: from clinical description to molecular genetics</article-title>
<source/>Mol Syndromol
          <year>2012</year>
<volume>2</volume>
<fpage>153</fpage>
<lpage>163</lpage>
<pub-id pub-id-type="pmid">22670136</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cellini</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Vignoli</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pisano</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The hyperkinetic movement disorder of FOXG1-related epileptic-dyskinetic encephalopathy</article-title>
<source/>Dev Med Child Neurol
          <year>2016</year>
<volume>58</volume>
<fpage>93</fpage>
<lpage>97</lpage>
<pub-id pub-id-type="doi">10.1111/dmcn.12894</pub-id>
<pub-id pub-id-type="pmid">26344814</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iourov</surname>
<given-names>IY</given-names>
</name>
<name>
<surname>Vorsanova</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Liehr</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kolotii</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Yurov</surname>
<given-names>YB</given-names>
</name>
</person-group>
<article-title>Increased chromosome instability dramatically disrupts neural genome integrity and mediates cerebellar degeneration in the ataxia-telangiectasia brain</article-title>
<source/>Hum Mol Genet
          <year>2009</year>
<volume>18</volume>
<fpage>2656</fpage>
<lpage>69</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddp207</pub-id>
<pub-id pub-id-type="pmid">19414482</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buckanovich</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>YY</given-names>
</name>
<name>
<surname>Darnell</surname>
<given-names>RB</given-names>
</name>
</person-group>
<article-title>The onconeural antigen Nova-1 is a neuron-specific RNA-binding protein, the activity of which is inhibited by paraneoplastic antibodies</article-title>
<source/>J Neurosci
          <year>1996</year>
<volume>16</volume>
<fpage>1114</fpage>
<lpage>22</lpage>
<pub-id pub-id-type="pmid">8558240</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Störchel</surname>
<given-names>PH</given-names>
</name>
<name>
<surname>Thümmler</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Siegel</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Aksoy-Aksel</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zampa</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Sumer</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A large-scale functional screen identifies Nova1 and Ncoa3 as regulators of neuronal miRNA function</article-title>
<source/>EMBO J
          <year>2015</year>
<volume>34</volume>
<fpage>2237</fpage>
<lpage>54</lpage>
<pub-id pub-id-type="doi">10.15252/embj.201490643</pub-id>
<pub-id pub-id-type="pmid">26105073</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>